SG11201408024TA - Method for obtaining monocytes or nk cells - Google Patents

Method for obtaining monocytes or nk cells

Info

Publication number
SG11201408024TA
SG11201408024TA SG11201408024TA SG11201408024TA SG11201408024TA SG 11201408024T A SG11201408024T A SG 11201408024TA SG 11201408024T A SG11201408024T A SG 11201408024TA SG 11201408024T A SG11201408024T A SG 11201408024TA SG 11201408024T A SG11201408024T A SG 11201408024TA
Authority
SG
Singapore
Prior art keywords
cells
tokyo
cell therapy
immune cell
present
Prior art date
Application number
SG11201408024TA
Inventor
Hiroyuki Abe
Hiroaki Kawasaki
Original Assignee
Hiroyuki Abe
Hiroaki Kawasaki
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hiroyuki Abe, Hiroaki Kawasaki filed Critical Hiroyuki Abe
Publication of SG11201408024TA publication Critical patent/SG11201408024TA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/02—Compounds of the arachidonic acid pathway, e.g. prostaglandins, leukotrienes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2301—Interleukin-1 (IL-1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2304—Interleukin-4 (IL-4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2306—Interleukin-6 (IL-6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2312—Interleukin-12 (IL-12)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/25—Tumour necrosing factors [TNF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/58—Adhesion molecules, e.g. ICAM, VCAM, CD18 (ligand), CD11 (ligand), CD49 (ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
    • C12N2506/115—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells from monocytes, from macrophages
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis

Abstract

(i2) mwu ft iz s-5 iv x m £ titz s issaj n d9) mm IHMMi (43) m&'&m a 2014^2^ 6 0(06.02.2014) WIPOIPCT (10) WO 2014/021070 A1 (51) C12N 5/0783 (2010.01) (21) (22) (25) C12N 5/0784 (2010.01) PCT/JP2013/068878 2013 ^ 7 M 10 0(10.07.2013) B^m (26) (30) fiBfcftf '— 1 4#Jg| 2012-172245 2012 ^8^ 2 0 (02.08.2012) JP (72) fccfci; (71) tfjSIA :JRTBP tf^(ABE, Hiroyuki) [JP/JP]; T 1830002 1—14 — 5 Tokyo (JP). JUlIf j£ BJ (KAWASAKI, Hiroaki) [JP/JP]; T 1070052 2-16-3-110 2 Tokyo (JP). (74) ftIA: (HARAKENZO WORLD PATENT & TRADEMARK); T 5300041 AK5J^AK5rfT^bE^W^f2Tg^b2 #6-^- Osaka (JP). (8i) (^ro&i^psy, 11^ oJ#£): AE, AG, AL, AM, AO, AT, AU, AZ, BA, (84) BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. V&tf nlfb): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), 3- — V T (AM, AZ, BY, KG, KZ, RU, TJ, TM), 3 — • V / ^ (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). - 21 ^(3)) o l> o i-H CJ o o CJ o & (54) Title: METHOD FOR OBTAINING MONOCYTES OR NK CELLS (57) Abstract: The present invention relates to a method whereby cells that can be used in immune cell therapy are separated from peripheral blood and propagated. The present invention enables immune system cells to be provided in number that a is sufficient for use in immune cell therapy. (57)®$: *f§0ji t, fo.frbmkL, *
SG11201408024TA 2012-08-02 2013-07-10 Method for obtaining monocytes or nk cells SG11201408024TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012172245A JP5856025B2 (en) 2012-08-02 2012-08-02 Methods for obtaining monocytes or NK cells
PCT/JP2013/068878 WO2014021070A1 (en) 2012-08-02 2013-07-10 Method for obtaining monocytes or nk cells

Publications (1)

Publication Number Publication Date
SG11201408024TA true SG11201408024TA (en) 2015-01-29

Family

ID=50027754

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201408024TA SG11201408024TA (en) 2012-08-02 2013-07-10 Method for obtaining monocytes or nk cells

Country Status (9)

Country Link
US (1) US10113148B2 (en)
EP (1) EP2881462B1 (en)
JP (1) JP5856025B2 (en)
KR (1) KR101732532B1 (en)
CN (2) CN109456940A (en)
CA (2) CA3048831C (en)
HK (2) HK1204655A1 (en)
SG (1) SG11201408024TA (en)
WO (1) WO2014021070A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101923848B1 (en) * 2013-01-15 2018-11-29 히로유키 아베 Method for manufacturing immunocyte-containing composition, and cancer-treating composition
KR101683614B1 (en) 2016-02-15 2016-12-07 신동혁 Culture Media Kits for NK cell Cultivation and NK cell Culture Method using the Same
JP7096639B2 (en) * 2016-12-21 2022-07-06 ジェムバックス アンド カエル カンパニー，リミティド Dendritic cell therapeutic agents and immunotherapeutic agents containing telomerase-derived peptides, and therapeutic methods using them.
CN107022525A (en) * 2017-04-28 2017-08-08 中卫华医（北京）医院管理有限公司 NK cell culture processes for oncotherapy
IL276365B2 (en) 2018-02-01 2023-10-01 Nkmax Co Ltd Method of producing natural killer cells and composition for treating cancer
CN109294985B (en) 2018-10-25 2022-02-18 江苏普瑞康生物医药科技有限公司 Culture medium system for NK cell in-vitro amplification and NK cell in-vitro amplification method
CN111454903B (en) 2020-05-06 2023-10-20 青岛瑞思德生物科技有限公司 Immune cell in vitro culture, induction, activation and cryopreservation method and cell bank establishment thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7566568B2 (en) * 2001-04-27 2009-07-28 Istituto Superiore Di Sanita Method for generating highly active human dendritic cells from peripheral blood mononuclear cells
JP4653465B2 (en) * 2004-10-25 2011-03-16 泰信 小林 Method for promoting natural killer cell proliferation and culture composition used therefor
JP4275680B2 (en) * 2006-04-28 2009-06-10 裕 照沼 Culture methods for lymphocyte activity / proliferation
US20100233192A1 (en) 2006-08-23 2010-09-16 Binex Co., Ltd. Manufacturing Method of Activated Lymphocytes for Immunotherapy
JP5447861B2 (en) 2008-03-28 2014-03-19 国立大学法人 岡山大学 Pharmaceutical composition for treating or preventing cancer that induces dendritic cell-like differentiation from monocytes and enhances anti-cancer immune activity
KR20090127973A (en) 2008-06-10 2009-12-15 주식회사 엔케이바이오 A method for cultivating self activated lymphocyte
JP2010259373A (en) * 2009-05-07 2010-11-18 Medeinetto:Kk Method for activating antigen-presenting cell
US20130011376A1 (en) * 2009-12-29 2013-01-10 Gamida Cell Ltd. Methods for Enhancing Natural Killer Cell Proliferation and Activity

Also Published As

Publication number Publication date
CA2876260C (en) 2020-08-04
WO2014021070A1 (en) 2014-02-06
CN104395461B (en) 2020-06-16
EP2881462A4 (en) 2016-01-06
KR20150029691A (en) 2015-03-18
CA2876260A1 (en) 2014-02-06
CA3048831C (en) 2021-04-13
CN109456940A (en) 2019-03-12
CN104395461A (en) 2015-03-04
HK1207108A1 (en) 2016-01-22
US20150197727A1 (en) 2015-07-16
EP2881462A1 (en) 2015-06-10
KR101732532B1 (en) 2017-05-04
CA3048831A1 (en) 2014-02-06
US10113148B2 (en) 2018-10-30
JP2014030375A (en) 2014-02-20
HK1204655A1 (en) 2015-11-27
JP5856025B2 (en) 2016-02-09
EP2881462B1 (en) 2020-05-06

Similar Documents

Publication Publication Date Title
SG11201408024TA (en) Method for obtaining monocytes or nk cells
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201804814YA (en) Materials and methods for delivering nucleic acids to cochlear and vestibular cells
SG11201900163PA (en) Macrocycle kinase inhibitors
SG11201807401RA (en) Therapeutic membrane vesicles
SG11201909949XA (en) Targeted immunotolerance
SG11201805451TA (en) Immune effector cell therapies with enhanced efficacy
SG11201407917PA (en) Highly efficient method for establishing artificial pluripotent stem cell
SG11201804510PA (en) Biparatopic polypeptides antagonizing wnt signaling in tumor cells
SG11201805950UA (en) Self-assembled nanostructures and separation membranes comprising aquaporin water channels and methods of making and using them
SG11201406903SA (en) Cell culture compositions and methods for polypeptide production
SG11201407417VA (en) Encoding and reconstruction of residual data based on support information
SG11201403106SA (en) Anti-phf-tau antibodies and their uses
SG11201407851RA (en) Synthesis of pyrrolo [2, 3 - b] pyridines
SG11201810628XA (en) Nasal pharmaceutical compositions with a porous excipient
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201810965YA (en) 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors
SG11201407745RA (en) Package body
SG11201408318RA (en) Compositions and methods for transmucosal absorption
SG11201908325PA (en) Process for the preparation of glucuronide drug-linkers and intermediates thereof
SG11201407844SA (en) Smoking agent and smoking device
SG11201406913VA (en) Text mining system, text mining method, and program
SG11201807827VA (en) Process for the preparation of pegylated drug-linkers and intermediates thereof
SG11201901351UA (en) A patient interface, system and method
SG11201805001UA (en) Method of treating influenza a